APTN-101

N/A

Report date: 2026/03/19 17:14:41

Base Information

Drug NameAPTN-101

Drug Alias NamehEGFRvIII-CD3 Bi-scFvBRiTEAPTN 101CBRX-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein +[4]

Mechanisms of ActionAnti-CD3Anti-EGFRvIII

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastomaGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAdaptin Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAdaptin Bio Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsGlioma

Other Information

ATC CodeN/A